Chief Growth Officer Buys $1.04M of Cybin Stock at $11.59
HELP has more than doubled off its 52-week low of $3.76 on light trading volume (0.2× avg).
Summary
Cybin's Chief Growth Officer bought $1.04M of stock on the open market at $11.59 per share, a massive personal bet on the company's Phase 3 depression drug program.
Key Events · Ownership and Investor Activity · HELP
-
CGO Buys $1.04M in Open Market
Chief Growth Officer Paul Glavine purchased 90,000 common shares at $11.5853 per share for $1,042,677 on August 31, 2026.
-
Massive Personal Stake
The purchase represents 75% of the company's market cap, making this an extraordinary insider conviction signal.
-
Post-Transaction Holdings
Glavine now directly holds 4,071,252 shares plus 230,941 shares indirectly via PLG Family Trust.
-
Voluntary Filing
The Form 4 was filed voluntarily — Glavine is not subject to Section 16 reporting requirements, making the disclosure itself notable.
Analysis · HELP · Life Sciences
Paul Glavine, Cybin's Chief Growth Officer, bought 90,000 shares on the open market for $1,042,677 at $11.5853 per share on August 31. This is a real-money purchase, not an option exercise or grant, and it comes just weeks after the company reported a $47.8M quarterly loss and confirmed its Phase 3 APPROACH data remains on track. The purchase size is enormous relative to the company's market cap, making this one of the most significant insider conviction signals possible for a company of this size.
How filings like this one have moved
In the 30 days to Oct 21, 2026, 43.9% of the 285 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.39%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HELP was trading at $12.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4M. The 52-week trading range was $3.76 to $14.35. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.